Function-oriented synthesis of marine phidianidine derivatives as potential PTP1B inhibitors with specific selectivity

Article abstract of DOI:10.3390/md16030097

Phidianidines A and B are two novel marine indole alkaloids bearing an uncommon 1,2,4-oxadiazole ring and exhibiting various biological activities. Our previous research showed that the synthesized phidianidine analogs had the potential to inhibit the activity of protein tyrosine phosphatase 1B (PTP1B), a validated target for Type II diabetes, which indicates that these analogs are worth further structural modification. Therefore, in this paper, a series of phidianidine derivatives were designed and rapidly synthesized with a function-oriented synthesis (FOS) strategy. Their inhibitory effects on PTP1B and T-cell protein tyrosine phosphatase (TCPTP) were evaluated, and several compounds displayed significant inhibitory potency and specific selectivity over PTP1B. The structure-activity relationship (SAR) and molecular docking analyses are also described.

Full text of DOI:10.3390/md16030097

marine drugs
Article
Function-Oriented Synthesis of Marine Phidianidine
Derivatives as Potential PTP1B Inhibitors with
Specific Selectivity
Jin Liu 1,2, Yu Chen 1, Jing-Ya Li 1, Cheng Luo 1,3, Jia Li 1,3, Kai-Xian Chen 1,3, Xu-Wen Li 1,3,* and
Yue-Wei Guo 1,3,
*
ID
1
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China; ljin080@mail.ustc.edu.cn (J.L.);
chenyu@simm.ac.cn (Y.C.); jyli@simm.ac.cn (J.-Y.L.); cluo@simm.ac.cn (C.L.); jli@simm.ac.cn (J.L.);
kxchen@simm.ac.cn (K.-X.C.)
Nano Science and Technology Institute, University of Science and Technology of China, 166 Ren Ai Road,
Suzhou 215123, China
Open Studio for Druggability Research of Marine Natural Products, Qingdao National Laboratory for
Marine Science and Technology, 1 Wenhai Road, Aoshanwei, Jimo, Qingdao 266237, China
Correspondence: xwli@simm.ac.cn (X.-W.L.); ywguo@simm.ac.cn (Y.-W.G.); Tel.: +86-21-5080-5813 (Y.-W.G.)
2
3
*
Received: 25 January 2018; Accepted: 7 March 2018; Published: 20 March 2018
Abstract: Phidianidines A and B are two novel marine indole alkaloids bearing an uncommon
1,2,4-oxadiazole ring and exhibiting various biological activities. Our previous research showed
that the synthesized phidianidine analogs had the potential to inhibit the activity of protein tyrosine
phosphatase 1B (PTP1B), a validated target for Type II diabetes, which indicates that these analogs are
worth further structural modification. Therefore, in this paper, a series of phidianidine derivatives
were designed and rapidly synthesized with a function-oriented synthesis (FOS) strategy. Their
inhibitory effects on PTP1B and T-cell protein tyrosine phosphatase (TCPTP) were evaluated, and
several compounds displayed significant inhibitory potency and specific selectivity over PTP1B. The
structure–activity relationship (SAR) and molecular docking analyses are also described.
Keywords: phidianidine; marine natural products; PTP1B inhibitor; specific selectivity; docking
analysis; Function Oriented Synthesis; structure-activity relationship
1. Introduction
Protein tyrosine phosphatase 1B (PTP1B) is well-recognized as a potential target for the treatment
of type II diabetes and obesity [1–5]. Many efforts have been made for the development of PTP1B
inhibitors, while their low selectivity over the other protein tyrosine phosphatases (PTPs) and poor
cell permeability are still two main issues, which prevent these compounds from being developed as
marketed drugs [6,7]. Therefore, searching for new specifically selective PTP1B inhibitors is of high
importance. In recent years, natural marine products have been regarded as new sources of potential
PTP1B inhibitors, since various marine-derived PTP1B inhibitory phenols, terpenes, alkaloids, and
terpene-alkaloid hybrids were isolated from algae, sponges, marine fungi, etc., with IC50 values ranging
from 0.8 to 15 µM [8]. Our group has long been engaged in the discovery of bioactive natural marine
products, with various novel molecules being isolated and structurally identified [9–11]. For example,
phidianidines A and B (Figure 1) are two unprecedented indole alkaloids, bearing an uncommon
1,2,4-oxadiazole ring and a terminal guanidine group, isolated from the marine opisthobranch mollusk
Phidiana militaris in 2011 [12]. These metabolites and their derivatives were found to exhibit significant
cytotoxic, DAT inhibitory, or neuroprotective activities [13–15].
Mar. Drugs 2018, 16, 97; doi:10.3390/md16030097
www.mdpi.com/journal/marinedrugs

Mar. Drugs 2018, 16, 97
2 of 14
Figure 1. Structures of phidianidines (1 and 2) and their protein tyrosine phosphatase 1B (PTP1B)
inhibitory analog 3.
Based on previously mentioned bioactivities of phidianidines, in 2016 our group designed a
series of new phidianidine analogs, and first reported their PTP1B inhibitory activities [16]. In this
previous work, we assumed that the guanidine group was not the required function group, according
to Lindersley’s research [14], and thus we did the preliminary function-oriented synthesis (FOS) of
the phidianidine analogs towards PTP1B inhibitors. Several synthesized products (e.g., compound 3
Figure 1) exhibited considerable inhibitory activities, with specific selectivity against other PTPs, such
as T-cell protein tyrosine phosphatase (TCPTP); in addition, their synthesis is easy in comparison
to the natural products with a guanidine group. However, there were still seven synthetic steps
involved in the route, with transition metals needed in two of them, which are not economical and
eco-friendly enough. Besides, whether the guanidine group is a required functionality or not for the
PTP1B inhibitory effect is still not confirmed. Therefore, further FOS and structure–activity relationship
(SAR) study are worthwhile, to be conducted towards more biologically-active yet affordable PTP1B
inhibitors. It is worth mentioning that TCPTP, a phosphatase implicated in regulating T-cell activation,
as a very important member of the PTP family, shows the highest homology to PTP1B. Therefore,
selective inhibitory effect on PTP1B over TCPTP is essential for anti-diabetic drug discovery. In this
,
paper, we prepared 40 phidianidine analogs (9a
synthetic routes, by simplifying the moiety on top of our previous result. The analogs’ PTP1B
inhibitory activities were evaluated and the SAR was investigated. All the compounds were subjected
–9e, 10a–10e, 13a–13i, and 14a–14u) with two different
C
to specific selectivity studies over TCPTP. A docking analysis of selected compounds 14c
14l−14n into the active site of PTP1B was also performed.
, 14p and
2. Results and Discussion
2.1. Initial Synthesis of Analogs and Biological Evaluation
The initial plan was to simplify the
in Scheme 1. The synthesis was similar as our previous reported route. The treatment of aryl aldehyde
4a−4d) hydroxylamine hydrochloride (NH2OH HCl), in the presence of sodium hydroxide (NaOH)
in 50% EtOH (in water), yielded oxime . Dehydration of with a dichloro(p-cymene)ruthenium(II)
dimer in acetonitrile (CH3CN) led to the nitrile 17], which further reacted with NH2OH HCl and
sodium bicarbonate (NaHCO3) in EtOH, affording amidoxime . Esterification of with 3-indoleacetic
acid in the presence of 2-(7-Azabenzotriazol-1-yl)-N,N,N ,N -tetramethyluronium hexafluorophosphate
(HATU) and N,N-diisopropylethylamine (DIPEA) in CH2Cl2 provided compound . Intramolecular
cyclization of in the presence of sodium acetate (NaOAc) in 30% EtOH under reflux gave rise to the
oxadiazole product 10 18]. In order to make sure that the guanidine group was not correlated for the
C moiety of compound 3 by removing one aryl ring, as shown
4
(
·
5
5
6
[
·
7
7
0
0
9
9
[
PTP1B inhibitory activity, the natural product phidianidine B (
Chamberland’s route [19].
2) was also synthesized by following

Mar. Drugs 2018, 16, 97
3 of 14
Scheme 1. Reagent and conditions:
(b) Dichloro(p-cymene)ruthenium(II) dimer, CH3CN, 80 C, 4 h; (
4 h; (d) HATU, DIPEA, CH2Cl2, r.t., 2 h; (e) NaOAc, 30% EtOH, reflux, overnight.
(
a
) NH2OH◦
·
HCl, NaOH, 50% EtOH, r.t., overnight;
c
) NH2OH HCl, NaHCO3, EtOH, r.t.,
·
The inhibitory activities of the synthesized phidianidine B ( ) and its analogs 9a–9e and 10a–10e
2
against PTP1B were measured, using p-nitrophenyl phosphate (pNPP) as a substrate. Oleanolic
acid, a known PTP1B inhibitor, was used as the positive control. The results are summarized in
Table 1. The primary bioassay results indicated that the initial FOS is unsatisfied, since only one
synthetic step was shortened, while just compound 10e displayed moderate PTP1B inhibitory activity,
with 50.5% inhibition (IC50 = 16.8 µM). Nevertheless, the preliminary SAR study suggested that the
1,2,4-oxadiazole was necessary for the activity, since the ring opening compounds 9a−9e showed no
effects. Moreover, the larger R group seemed to be helpful for the biological effect, as revealed by the
inhibition percentage of 10c−10e, while the guanidine chain was proved to be unwanted as showed
by the inhibition rate of 2.
Table 1. Inhibitory activity of compounds 9a–9e and 10a–10e on PTP1B.
Compd.
R
% Inhibition (20 µM)
Compd.
R
% Inhibition (20 µM)
9a
9b
9c
9d
9e
H
F
Cl
7.3 ± 6.8
14.0 ± 4.3
5.2 ± 1.8
9.8 ± 7.1
23.4 ± 3.7
23.5 ± 2.6
10a
10b
10c
10d
10e
H
F
Cl
2.4 ± 1.2
19.8 ± 0.1
40.0 ± 7.6
44.5 ± 0.3
50.5 ± 1.1
1.2 ± 0.1 µM
NO2
CH2CH3
NO2
CH2CH3
Phidianidine B (2)
Oleanolic acid (IC50)
2.2. Second Round Synthesis and Biological Evaluation
In order to shorten the synthetic steps, and to efficiently obtain more analogs for further biological
evaluation, we decided to change the linkage of the and moieties from the C-5 position of the
A
B
1,2,4-oxadiazole in compound 10 to its C-3 position in compound 14, as displayed in Scheme 2, of
which the synthetic steps could then be greatly reduced to three or two steps. With this strategy,
we first synthesized compound 14a as the aforementioned
evaluated its PTP1B inhibitory activity. Fortunately, 14a exhibited the similar effect as 10e, with an
IC50 value of 13.5 M, which proved that the linkage position of the 1,2,4-oxadiazole has no obvious
B moiety isomer of compound 10e, and
µ
influence on the activity. Therefore, starting from 3-indoleacetonitrile (11), by using the synthetic
routes shown in Scheme 2, a nucleophile was added, followed by esterification with either carboxylic
acids or acyl chlorides and an immediate 1,2,4-oxadiazole ring closing under reflux, yielding a number
of 14a analogs 14b–14u. It is worth mentioning that when treating compound 13i in the presence
of NaOAc under reflux in order to close the 1,2,4-oxadiazole ring, the bromine group has also been
substituted by acetoxyl group towards compound 14i.

Mar. Drugs 2018, 16, 97
4 of 14
◦
HCl, NaHCO3, EtOH, 65 C, 4 h; (b) for 14a–14k, and
Scheme 2. Reagent and conditions: (
14p 14u: i, carboxylic acid, HATU, DIPEA, CH2Cl2, r.t., 2 h; ii, NaOAc, 30% EtOH, reflux, overnight.
(c) For 14l–14o, acyl chloride, K2CO3, toluene, reflux, 4 h.
a) NH2OH
·
–
In fact, compounds 14b
was based on the previous results of 10e and 14a, of which different substitutes were introduced
to the benzene ring of the moiety, including nucleophilic and electrophilic groups. As indicated
from the PTP1B inhibitory results of 14a 14h in Table 2, the length of the alkyl side chain on the
benzene ring played a highly important role on the activity. Compound 14c, possessing the longest
hexyl chain, exhibited the strongest PTP1B inhibitory activity, with an IC50 value of 4.9 M. Other
nucleophilic groups, such as methoxyl (14f), or an electrophilic group like trifluoromethyl (14d
showed no activity at 20 M. The second direction was to replace the phenyl group with aliphatic and
naphthenic substitutions towards 14h 14n, of which the compounds comprising naphthenic groups
such as cyclobutyl (14l) and cyclohexyl (14n) displayed significant PTP1B inhibitory activities, with
IC50 values of 8.6 and 5.3 M, respectively. The last route was to replace the phenyl group on other
aromatic rings, such as pyridine and indole, towards 14o 14u. As can be observed from the results
in Table 2, the introduction of the pyridine ring (for 14o) has no influence on improving inhibitory
activity, while the indole ring greatly improved the effect, with IC50 values ranging from 5.8 to 9.7
for compounds 14p 14u, among which 14p (IC50 = 5.8 M) is the strongest PTP1B inhibitor. The SAR
–14u were designed and synthesized in three directions. The first one
C
–
µ
)
µ
–
µ
–
µM
–
µ
analysis revealed that the presence of the halogen substitutions reduced inhibitory activity, with the
F group shown to be the worst. In addition, the 1,2,4-oxadiazole group was further confirmed to be
necessary for inhibitory activity, since the ring opening compounds 13a−13c all showed no activity
comparing to the corresponding 14a−14c.
The selectivity of all the PTP1B inhibitory compounds was also evaluated against TCPTP. As
shown in Table 3, none of the compounds showed significant inhibitory activities against TCPTP at
the concentration of 20 µM, suggesting highly specific selectivity of these molecules towards PTP1B.
Among them, compound 14n showed the lowest inhibitory percentage at 20
indicating the highest selectivity of 14n on PTP1B.
µM against TCPTP,

Mar. Drugs 2018, 16, 97
5 of 14
Table 2. Inhibitory activity of compounds 13a–13i and 14a–14u on PTP1B.
Compd.
13a
X
IC50 (µM)
Compd.
14a
X
IC50 (µM)
13.5 ± 0.6
>20
13b
13c
>20
>20
14b
14c
7.1 ± 0.1
4.9 ± 0.8
13d
13e
13f
>20
>20
>20
14d
14e
14f
>20
>20
>20
13g
>20
14g
>20
13h
13i
14j
(CH2)3CH3
(CH2)4Br
CH(CH3)2
>20
>20
>20
14h
14i
14k
(CH2)3CH3
(CH2)4O2CCH3
CH(Cl)2
>20
>20
>20
14l
8.6 ± 1.5
5.3 ± 0.7
14m
14o
>20
>20
14n
14p
5.8 ± 0.1
14q
>20
14r
14t
7.9 ± 0.6
8.7 ± 0.9
14s
7.4 ± 0.1
9.7 ± 1.7
14u
Table 3. Inhibitory activity of PTP1B inhibitory compounds on T-cell protein tyrosine phosphatase
(TCPTP) a.
% Inhibition
% Inhibition
% Inhibition
Compd.
Compd.
Compd.
(20 µM)
(20 µM)
(20 µM)
10e
14a
14b
15.84
9.22
50.31
14l
14n
14p
25.52
11.68
55.17
14s
14t
14u
34.51
54.35
38.74
Oleanolic
acid (IC50
14c
54.18
14r
38.29
3.24 µM
)
a Compounds possessing IC50 values less than 20
µM on PTP1B were evaluated for their TCPTP inhibitory activities.

Mar. Drugs 2018, 16, 97
6 of 14
2.3. Structure–Activity Relationship and Docking Analyses
In summary, the FOS of phidianidine analogs led to the discovery of three different PTP1B
inhibitory compounds—14c 14n, and 14p—with IC50 values of 4.9, 5.3, and 5.8 M, respectively. From
,
µ
the structures of all the three compounds, and based on the preliminary SAR study, we speculate that
the strong activity of compound 14c might be due to the long chain well filling the ligand-binding
pocket of the PTP1B protein. The improved activity of 14p compared to the other aromatic analogs
could possibly be attributed to the hydrogen bond interaction of its NH with the amino acid residue of
PTP1B. However, the significant activity of the cyclohexyl-substituted compound 14n was difficult to
explain. On the basis of the above speculation, and in order to understand the inhibitory mechanism
of the most active compounds against PTP1B, compounds 14c, 14n, and 14p were initially selected to
perform the molecular docking analysis [10]. The X-ray crystal structure of PTP1B, with a resolution of
2.50 Å (Protein Data Bank, 2QBP), was used for the docking studies. Figure 2 displays the binding
mode of the selected compounds with PTP1B. For 14c, we can easily observe the long chain filling
the ligand-binding pocket of the PTP1B protein (Figure 2, docking figure of 14c showing surface).
Moreover, the alkyl chain on the benzene ring overlapped with the PHE182 amino acid residue, and the
benzene ring helped to induce the alkyl chain into the right pocket; otherwise, the flexible long alkyl
chain cannot fill the inner space, which reasonably explains the disappearance of the inhibitory activity
for 14h and 14i (Figure 2). In addition, the N–H on the oxadiazole ring of 14c formed a hydrogen bond
interaction with the glutamate residues (GLN262), which enhanced its activity. For 14p and 14n, the
N–H on the indole ring can form a hydrogen bond interaction with the aspartic acid residue (ASP48)
of PTP1B. In addition, Figure 2 showed that the cyclohexyl of 14n and the other indole ring of 14p
could fill the inner space of the pocket with the appropriate molecular size. However, it is still difficult
to explain the lack of activity for compound 14m, since its cyclopentyl moiety seems to have no big
difference to the cyclohexyl on 14n. Therefore, the 14n analogs 14l and 14m were also applied for
the docking analysis, and interestingly, 14m showed totally different docking results from those of
14l and 14n, with the cyclopentane ring on the opposite site of the pocket (Figure 2). Besides, there
were no bond interactions between 14m and PTP1B, which further explained the disappearance of its
inhibitory activity. For 14l, although no bond interactions were found, its cyclobutane ring was small
enough to go deeply into the pocket (Figure 2), which guaranteed the relatively strong activity. Finally,
the molecular docking results rationally explained the PTP1B activity of the synthetic compounds and
supported our SAR analysis. Compound 14n, as the most selective candidate over PTP1B, should be
further modified on its cyclohexane ring by adding a long alkyl chain and hydrogen bond donor to
form a better interaction structure for binding to PTP1B with stronger activity and better selectivity.
This research would thus give an insight on the discovery of novel specific PTP1B inhibitors from
marine sources towards anti-diabetes drugs.
Figure 2. Docking results for compounds 14c
, 14p, and 14l–14n on PTP1B, respectively (upper row:
without showing surface of PTP1B, lower row: showing surface of PTP1B).

Mar. Drugs 2018, 16, 97
7 of 14
3. Experimental Section
3.1. Chemistry
All the chemicals were obtained from commercial sources. The NMR spectra were measured
on Bruker Avance spectrometers (400 MHz for 1H; Avance III 400, and 125 MHz for 13C; Avance III
500, Bruker Biospin AG, Uster, Switzerland). Chemical shifts were expressed in
δ (ppm) and coupling
constants (J) in Hz. Commercial Silica gel (200–300 mesh, Sinopharm Chemical Reagent Co., Ltd.,
Shanghai, China) was used for column chromatography and pre-coated Silica gel plates (HSGF254,
Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) were used for analytical TLC. ESI-MS
spectra were recorded on a Q-TOF Micromass spectrometer (1290-6545 UHPLC-QTOF, Micromass,
Wythenshawe, UK).
3.1.1. General Synthetic Procedure of Oxime 5 and Nitrile 6
To a solution of aldehyde
4 (9.4 mmol, 1.0 equiv) in EtOH (30 mL) was added hydroxylamine
hydrochloride (11.3 mmol, 1.2 equiv) and sodium hydroxide (18.8 mmol, 2.0 equiv). The mixture
was stirred at room temperature overnight. EtOH was removed in vacuo. The residue was added
water and extracted with ethyl acetate (3
anhydrous MgSO4, and concentrated. The residue was subjected to silica gel chromatography with
petroleum ether/CH2Cl2 (3:2) to make oxime . To a solution of oxime (6.0 mmol, 1.0 equiv) in
acetonitrile was added [Ru2(p-PriC6H4Me)2(
-Cl)Cl]2 (0.3 mmol, 0.05 equiv) and refluxed for 4 h. The
×
30 mL), washed with brine (3
×
30 mL), dried over
5
5
µ
mixture was filtered, and the filtrate was concentrated in vacuo. The residue was subjected to silica gel
chromatography with petroleum ether/CH2Cl2 (2:1) to make nitrile 6.
3.1.2. Synthesis of Carboxamidine 7
To a solution of nitrile
6 (3.3 mmol, 1.0 equiv) in EtOH (15 mL) was added hydroxylamine
hydrochloride (4.0 mmol, 1.2 equiv) and NaHCO3 (6.6 mmol, 2.0 equiv). The mixture was refluxed
for 4 h. The reaction mixture was diluted with EtOAc, filtered, and concentrated in vacuo. Water was
added to the residue and extracted with ethyl acetate (3
over anhydrous MgSO4, and concentrated. The residue was subjected to silica gel chromatography
× 30 mL), washed with brine (1 × 30 mL), dried
with EtOAc/MeOH (9:1) to make carboxamidine 7.
3.1.3. Synthesis of Carboxamidine 9
To a solution of 3-indoleacetic acid (3.6 mmol, 1.0 equiv) in CH2Cl2 (20 mL), DIPEA (4.7 mmol,
1.3 equiv) and HATU (3.6 mmol, 1.0 equiv) were added, and the reaction mixture was stirred for
30 min, then carboxamidine
7 (3.6 mmol, 1.0 equiv) dissolved in CH2Cl2 (10 mL) was added and
stirred for 2 h. The mixture was filtered and the residue was washed with CH2Cl2, after which the
solution was combined and concentrated. The residue was subjected to silica gel chromatography
with petroleum ether/EtOAc (2:1) to give carboxamidine 9.
9a: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
1H), 7.61 (d, J = 7.45 Hz, 1H), 7.50 (t, J = 7.66 Hz, 2H), 7.35 (d, J = 8.12 Hz, 1H), 7.27 (s, 1H), 7.11 (t,
δ 8.13 (d, J = 7.15 Hz, 1H), 7.70 (d, J = 7.78 Hz,
1H), 7.03 (t, 1H), 3.73 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ 166.42, 161.34, 138.25, 134.25, 130.70,
130.55, 129.64, 128.49, 125.03, 122.67, 120.01, 119.63, 112.29, 109.59, 28.25; HR-ESIMS: [M + H]+ calcd.
for C17H16N3O2 294.1237, found: 294.1231.
9b: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
(s, 1H), 7.15 (m, 3H), 7.05 (t, 1H), 3.96 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ
7.75 (m, 2H), 7.64 (d, 1H), 7.37 (d, 1H), 7.25
172.08, 164.41, 158.89,
δ
137.69, 130.55, 130.46, 128.58, 127.79, 124.95, 122.60, 120.03, 119.51, 116.54, 116.32, 112.41, 108.40, 30.80;
HR-ESIMS: [M + H]+ calcd. for C17H15FN3O2 312.1143, found: 312.1144.

Mar. Drugs 2018, 16, 97
8 of 14
9c: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
δ 7.70 (d, J = 8.79 Hz, 2H), 7.62 (d, J = 6.72 Hz,
1H), 7.43 (d, J = 8.79 Hz, 2H), 7.36 (d, J = 8.10 Hz, 1H), 7.25 (s, 1H), 7.11 (t, 1H), 7.06 (t, 1H), 3.96
(s, 2H); 13C NMR (125 MHz, CD3OD):
128.81, 128.61, 124.84, 122.58, 120.02, 119.42, 112.38, 108.37, 30.91; HR-ESIMS: [M
C17H13ClN3O2 326.0702, found: 326.0705.
δ
172.08, 158.85, 138.08, 137.85, 131.44, 129.81, 129.74, 129.57,
−
H]− calcd. for
9d: White solid, Yield 90%; 1H NMR (400 MHz, CD3OD):
2H), 7.64 (d, J = 7.92 Hz, 1H), 7.37 (d, J = 8.06 Hz, 1H), 7.26 (s, 1H), 7.12 (t, 1H), 7.06 (t, 1H), 3.98 (s, 2H);
13C NMR (125 MHz, CD3OD):
172.00, 157.92, 150.69, 138.90, 138.09, 129.53, 124.87, 124.56, 122.60,
δ 8.28 (d, J = 9.07 Hz, 2H), 7.96 (d, J = 9.07 Hz,
δ
120.03, 119.41, 112.40, 108.29, 30.85; HR-ESIMS: [M
337.0952.
−
H]− calcd. for C17H13N4O4 337.0942, found:
9e: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
7.12 (t, 1H), 7.05 (t, 1H), 3.96 (s, 2H), 2.67 (m, 2H), 1.23 (t, 3H); 13C NMR (125 MHz, CD3OD):
δ
7.63 (m, 3H), 7.36 (d, 1H), 7.26 (m, 3H),
172.15,
δ
159.95, 148.71, 138.09, 130.05, 129.03, 128.63, 128.21, 124.82, 122.58, 120.02, 119.43, 112.37, 108.46, 30.97,
29.68, 15.89; HR-ESIMS: [M + H]+ calcd. for C19H20N3O2 322.1550, found: 322.1543.
3.1.4. Synthesis of Compound 10
A solution of carboxamidine
in 30% EtOH/H2O (10 mL) was refluxed overnight. The EtOH was removed in vacuo, and the
residue was added to water and extracted with ethyl acetate (3 30 mL), then washed with brine
1 × 30 mL), dried over anhydrous MgSO4, and concentrated. The residue was subjected to silica gel
chromatographic with petroleum ether/EtOAc (5:1) to make compound 10.
9 (3.2 mmol, 1.0 equiv) and sodium acetate (6.4 mmol, 2.0 equiv)
×
(
10a: White solid, Yield 94%; 1H NMR (400 MHz, CD3OD):
8.10 (d, J = 7.05 Hz, 1H), 7.63 (d, 2H), 7.56
(d, 2H), 7.35(d, J = 8.13 Hz, 1H), 7.23 (s, 1H), 7.10 (t, 1H), 7.01 (t, 1H), 4.27(s, 2H); 13C NMR (125 MHz,
CD3OD): 177.04, 172.0, 138.17, 134.06, 130.36, 129.02, 128.41, 125.39, 124.55, 122.59, 119.91, 119.37,
112.33, 109.82, 23.39; HR-ESIMS: [M + H]+ calcd. for C17H14N3O 276.1131, found: 276.1125.
10b: White solid, Yield 92%; 1H NMR (400 MHz, CD3OD):
7.92 Hz, 1H), 7.37 (d, J = 8.14 Hz, 1H), 7.28 (s, 1H), 7.23 (t, 2H), 7.12 (t, 1H), 7.03 (t, 1H),4.46(s, 2H); 13
NMR (125 MHz, CD3OD): 181.15, 168.75, 164.99, 138.12, 130.73, 130.66, 128.16, 124.80, 124.60, 122.79,
δ
δ
δ
8.08 (d, 1H), 8.06 (d, 1H), 7. 58 (d, J =
C
δ
120.19, 119.16, 117.09, 116.91, 112.46, 108.06, 24.01; HR-ESIMS: [M
292.0892, found: 292.0886.
−
H]− calcd. for C17H11FN3O
10c: White solid, Yield 92%; 1H NMR (400 MHz, CD3OD):
Hz, 1H), 7. 50 (d, J = 8.74 Hz, 2H), 7.37 (d, J = 8.14 Hz, 1H), 7.28 (s, 1H), 7.12 (t, 1H), 7.04 (t, 1H), 4.47 (s,
2H); 13C NMR (125 MHz, CD3OD):
181.27, 168.77, 164.99, 138.34, 138.12, 130.27, 129.86, 128.16, 126.92,
δ 8.01 (d, J = 8.75 Hz, 2H), 7.92 (d, J = 7.92
δ
124.79, 122.79, 120.19, 119.15, 112.46, 108.03, 24.02; HR-ESIMS: [M
308.0596, found: 308.0596.
−
H]− calcd. for C17H11ClN3O
10d: White solid, Yield 90%; 1H NMR (400 MHz, dimethyl sulfoxide (DMSO)-d6, not soluble in MeOH
or CHCl3): 8.38 (d, J = 8.98 Hz, 2H), 8.24 (d, J = 8.98 Hz, 2H), 7.57 (d, J = 7.80 Hz, 1H), 7.43 (s, 1H),
7.39 (d, J = 8.11 Hz, 1H), 7.11 (t, 1H), 7.02 (t, 1H), 4.56 (s, 2H); 13C NMR (125 MHz, DMSO-d6):
180.31,
δ
δ
166.43, 149.13, 136.17, 132.05, 128.39, 126.61, 124.49, 124.44, 121.37, 118.86, 118.19, 111.63, 106.21, 22.76;
HR-ESIMS: [M − H]− calcd. for C17H11N4O3 319.0837, found: 319.0835.
10e: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 7.66 (t, 1H), 5.07 (m, 2H), 3.93 (s, 2H), 1.87 (m, 3H); 13C NMR (125 MHz, CD3OD):
δ
8.55 (t, 2H), 8.20 (t, 1H), 7.94 (m, 4H), 7.73
180.87,
δ
169.54, 149.26, 138.12, 129.47, 128.40, 128.17, 125.52, 124.78, 122.78, 120.18, 118.17, 112.45, 108.11, 29.79,
24.03, 15.82; HR-ESIMS: [M + H]+ calcd. for C19H18N3O 304.1444, found: 304.1450.

Mar. Drugs 2018, 16, 97
9 of 14
3.1.5. Synthesis of Carboxamidine 12
To a solution of compound 11 (64.1 mmol, 1.0 equiv) in EtOH (60 mL) was added hydroxylamine
hydrochloride (96.2 mmol, 1.5 equiv) and NaHCO3 (192.3 mmol, 3.0 equiv). The mixture was stirred
for 4 h at 65 ◦C. The reaction mixture was diluted with EtOAc, filtered and concentrated in vacuo.
Water was added to the residue and extracted with ethyl acetate (3
×
100 mL), washed with brine
(1 × 100 mL), dried over anhydrous MgSO4, and concentrated. The residue was subjected to silica gel
chromatography with EtOAc /MeOH (9:1) to make carboxamidine 12.
3.1.6. Synthesis of Carboxamidine 13
To a solution of carboxylic acid (0.8 mmol, 1.0 equiv) in CH2Cl2 (5 mL), DIPEA (1.0 mmol,
1.3 equiv) and HATU (0.8 mmol, 1.0 equiv) were added, and the reaction mixture was stirred for
30 min, after which compound
7 (0.8 mmol, 1.0 equiv) in CH2Cl2 (2 mL) was added and stirred
for 2 h. The mixture was filtered, the residue was washed with CH2Cl2, and then the solution was
combined and concentrated. The residue was subjected to silica gel chromatography with petroleum
ether/EtOAc (2:1) to give 13.
13a: White solid, Yield 88%; 1H NMR (400 MHz, CD3OD):
(s, 1H), 7.11 (t, 1H), 7.03 (t, 1H), 3.72 (s, 2H), 2.72 (q, 2H), 1.25 (t, 3H); 13C NMR (125 MHz, CD3OD):
δ 8.04 (d, 2H), 7.70 (d, 1H), 7.34 (m, 3H), 7.27
δ
166.44, 161.22, 151.46, 138.26, 130.74, 129.13, 125.01, 122.66, 120.01, 119.66, 112.28, 109.65, 29.89, 28.26,
15.73; HR-ESIMS: [M + H]+ calcd. for C19H20N3O2 322.1550, found: 322.1555.
13b: White solid, Yield 82%; 1H NMR (400 MHz, CD3OD):
(d, 2H), 7.26 (s, 1H), 7.11 (t, 1H), 7.02 (t, 1H), 3.72 (s, 2H), 2.69 (t, 2H), 1.61 (m, 2H), 1.37 (m, 2H), 0.94 (t,
δ 8.03 (d, 2H), 7.70 (d, 1H), 7.35 (d, 1H), 7.31
3H); 13C NMR (125 MHz, CD3OD):
δ 166.45, 161.22, 150.08, 138.25, 130.64, 129.69, 125.01, 122.66, 120.01,
119.65, 112.28, 109.64, 36.62, 34.54, 28.26, 23.32, 14.20; HR-ESIMS: [M + H]+ calcd. for C21H24N3O2
350.1863, found: 350.1870.
13c: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
(d, 2H), 7.26 (s, 1H), 7.11 (t, 1H), 7.02 (t, 1H), 3.72 (s, 2H), 2.68 (t, 2H), 1.64 (m, 2H), 1.32 (m, 6H), 0.89
δ 8.03 (d, 2H), 7.70 (d, 1H), 7.35 (d, 1H), 7.30
(t, 3H); 13C NMR (125 MHz, CD3OD):
δ 166.46, 161.22, 150.10, 138.25, 130.64, 129.69, 125.01, 122.66,
120.01, 119.65, 112.28, 109.64, 36.92, 32.81, 32.31, 29.99, 28.26, 23.63, 14.37; HR-ESIMS: [M + H]+ calcd.
for C23H28N3O2 378.2176, found: 378.2182.
13d: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
(d, 1H), 7.29 (t, 2H), 7.26 (s, 1H), 7.22 (t, 1H), 7.11 (t, 1H), 7.04 (t, 1H), 3.72 (s, 2H); 13C NMR (125 MHz,
δ 8.01 (t, 1H), 7.69 (d, 1H), 7.61 (m, 1H), 7.35
CD3OD): δ 164.04, 164.01, 161.96, 161.55, 138.23, 136.05, 135.98, 133.15, 128.46, 125.57, 125.54, 125.03,
122.67, 120.02, 119.60, 119.11, 119.03, 118.03, 117.85, 112.30, 109.45, 28.02; HR-ESIMS: [M + H]+ calcd.
for C17H15FN3O2 312.1143, found: 312.1144.
1
13e: White solid, Yield 85%; H NMR (400 MHz, CD3OD):
δ 8.32 (d, J = 8.14 Hz, 2H), 7.81 (d, J =
8.28 Hz, 2H), 7.70 (d, J = 7.91 Hz,1H), 7.35 (d, J = 8.14 Hz, 1H), 7.27 (s, 1H), 7.11 (t, 1H), 7.02 (t, 1H), 3.73
(s, 2H); 13C NMR (125 MHz, CD3OD):
δ 165.01, 161.67, 138.26, 135.23, 134.42, 131.27, 131.17, 128.48,
126.60, 126.57, 125.03, 122.67, 120.01, 119.65, 112.29, 109.59, 28.25; HR-ESIMS: [M + H]+ calcd. for
C18H15F3N3O2 362.1111, found: 362.1112.
1
13f: White solid, Yield 85%; H NMR (400 MHz, CD3OD):
δ 8.08 (d, J = 8.97 Hz, 2H), 7.70 (d, J =
7.92 Hz, 1H), 7.35 (d, J = 8.12 Hz, 1H), 7.26 (s, 1H), 7.11 (t, J = 7.56 Hz, 1H), 7.04 (s, 1H), 6.99 (t, J = 9.00
Hz, 1H), 3.85 (s, 2H), 3.71 (s, 3H); 13C NMR (125 MHz, CD3OD):
δ 166.23, 165.19, 161.09, 138.25, 132.63,
128.50, 125.00, 122.78, 122.66, 120.00, 119.66, 114.88, 112.28, 109.66, 55.99, 28.27; HR-ESIMS: [M + H]+
calcd. for C18H18N3O3 324.1343, found: 324.1347.

Mar. Drugs 2018, 16, 97
10 of 14
13g: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
δ
7.69 (d, 1H), 7.56 (d, 1H), 7.35 (d, 1H), 7.33
(d, 1H), 7.26 (s, 1H), 7.11 (t, 1H), 7.01 (m, 2H), 3.81 (s, 3H), 3.71 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ
166.11, 161.55, 160.37, 138.24, 135.87, 134.49, 128.47, 125.04, 122.67, 120.03, 119.80, 119.63, 117.40, 112.29,
111.77 109.46, 56.24, 28.05; HR-ESIMS: [M + H]+ calcd. for C18H17BrN3O3 402.0448, found: 402.0445.
13h: White solid, Yield 85%; 1H NMR (400 MHz, CD3OD):
7.10 (t, 1H), 7.01 (t, 1H), 3.63 (s, 2H), 2.43 (t, 2H), 1.65 (m, 2H), 1.40 (m, 2H), 0.94 (t, 3H); 13C NMR
(125 MHz, CD3OD): 173.57, 160.85, 138.21, 128.45, 124.93, 122.62, 119.93, 119.63, 112.25, 109.63, 33.38,
28.23, 28.12, 23.30, 14.07; HR-ESIMS: [M + H]+ calcd. for C15H20N3O2 274.1550, found: 274.1553.
δ 7.64 (d, 1H), 7.34 (d, 1H), 7.21 (s, 1H),
δ
13i: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 7.00 (t, 1H), 3.63 (s, 2H), 3.47 (t, 2H), 2.47 (t, 2H), 1.91 (m, 2H), 1.82 (m, 2H); 13C NMR (125 MHz,
δ 7.64 (d, 1H), 7.34 (d, 1H), 7.22 (s, 1H), 7.10
CD3OD): δ 173.07, 160.95, 138.21, 128.44, 124.93, 122.62, 119.94, 119.63, 112.25, 109.63, 33.72, 33.23, 32.63,
28.12, 24.65; HR-ESIMS: [M + H]+ calcd. for C15H19BrN3O2 352.0655, found: 352.0663.
3.1.7. Synthesis of Compound 14
A solution of compound
EtOH/H2O (5 mL), was refluxed overnight. The EtOH was removed in vacuo, the residue was added
with water and extracted with ethyl acetate (3 5 mL), washed with brine (1 5 mL), dried over
9 (0.4 mmol, 1.0 equiv) and sodium acetate (0.8 mmol, 2.0 equiv) in 30%
×
×
anhydrous MgSO4, and concentrated. The residue was subjected to silica gel chromatography with
petroleum ether/EtOAc (5:1) to give compound 14.
14a: White solid, Yield 84%; 1H NMR (400 MHz, CD3OD):
(d, 1H), 7.22 (s, 1H), 7.09 (t, 1H), 7.01 (t, 1H), 4.24 (s, 2H), 2.71 (q, 2H), 1.25 (t, 3H); 13C NMR (125 MHz,
CD3OD): 177.14, 171.85, 151.36, 138.15, 129.83, 129.13, 124.53, 122.57, 119.90, 119.37, 112.32, 109.84,
29.89, 23.38, 16.63; HR-ESI: [M + H]+ calcd. for C19H18N3O 304.1444, found: 304.1447.
δ 7.99 (d, 2H), 7.59 (d, 1H), 7.37 (d, 2H), 7.34
δ
14b: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
7.22 (s, 1H), 7.09 (t, 1H), 7.02 (t, 1H), 4.25 (s, 2H), 2.68 (t, 2H), 1.61 (m, 2H), 1.36 (m, 2H), 0.94 (t, 3H);
δ 7.98 (d, 2H), 7.59 (d, 1H), 7.34 (m, 3H),
13C NMR (125 MHz, CD3OD):
δ 177.15, 171.85, 150.01, 138.15, 130.39, 129.05, 124.53, 122.58, 119.90,
119.37, 112.32, 109.84, 36.62, 34.47, 23.39, 23.32, 14.19; HR-ESI: [M + H]+ calcd. for C21H22N3O 332.1757,
found: 332.1754.
14c: White solid, Yield 86%; 1H NMR (400 MHz, CD3OD):
(s, 1H), 7.09 (t, 1H), 7.00 (t, 1H), 4.24 (s, 2H), 2.65 (t, 2H), 1.61 (m, 2H), 1.31 (m, 6H), 0.88 (t, 3H); 13
δ 7.97 (d, 2H), 7.59 (d, 1H), 7.34 (m, 3H), 7.21
C
NMR (125 MHz, CD3OD):
δ 177.13, 171.83, 150.00, 138.14, 130.36, 129.03, 124.53, 122.57, 119.90, 119.37,
112.32, 109.84, 36.91, 32.79, 32.23, 29.98, 23.61, 23.29, 14.37; HR-ESI: [M + H]+ calcd. for C23H26N3O
360.2070, found: 360.2073.
14d: White solid, Yield 82%; 1H NMR (400 MHz, CD3OD):
7.23 (s, 1H), 7.09 (t, 1H), 7.01 (t, 1H), 4.29 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ
8.09 (t, 1H), 7.63 (m, 2H), 7.35 (m, 3H),
174.00, 171.73, 163.05,
δ
160.99, 138.14, 136.20, 136.13, 131.93, 128.39, 126.10, 126.08, 124.57, 122.58, 119.91, 119.39, 118.19, 118.02,
113.76, 112.32, 109.79, 23.32; HR-ESI: [M + H]+ calcd. for C17H13FN3O 294.1037, found: 294.1035.
14e: White solid, Yield 91%; 1H NMR (400 MHz, CD3OD):
2H), 7.60 (s, 2H), 7.34 (d, J = 8.13 Hz, 1H), 7.23 (s, 1H), 7.09 (t, J = 7.58 Hz, 1H), 7.01 (t, J = 7.50 Hz, 1H),
δ 8.27 (d, J = 8.16 Hz, 2H), 7.86 (d, J = 8.27 Hz,
4.28 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ 175.67, 172.34, 138.15, 135.23, 134.97, 129.72, 128.88, 128.38,
127.32, 127.29, 126.17, 124.59, 124.00, 122.60, 119.93, 119.36, 112.34, 109.72, 23.36; HR-ESIMS: [M + H]+
calcd. for C18H13F3N3O 344.1005, found: 344.1010.

Mar. Drugs 2018, 16, 97
11 of 14
14f: White solid, Yield 90%; 1H NMR (400 MHz, CD3OD):
δ
8.04 (d, 2H), 7.59 (d, 1H), 7.34 (d, 1H),
7.22 (s, 1H), 7.09 (m, 2H), 7.01 (t, 2H), 4.23 (s, 2H), 3.88 (s, 3H); 13C NMR (125 MHz, CD3OD):
δ 176.99,
171.76, 165.01, 138.17, 131.00, 128.42, 124.53, 122.57, 119.90, 119.37, 117.66, 115.75, 112.32, 109.88, 56.10,
23.38; HR-ESI: [M + H]+ calcd. for C18H16N3O2 306.1237, found: 306.1234.
14g: White solid, Yield 90%; 1H NMR (400 MHz, CD3Cl, in methanol dissolved is not good):
(d, 1H), 7.60 (d, 1H), 7.46 (d, 1H), 7.36 (m, 1H), 7.21 (m, 2H), 7.14 (t, 1H), 6.94 (dd, 1H), 4.34 (s, 2H),
δ 7.76
3.82 (s, 3H); 13C NMR (125 MHz, CD3Cl):
δ 174.77, 170.16, 158.86, 136.37, 135.62, 127.25, 126.40, 123.14,
122.46, 120.00, 119.84, 119.23, 116.71, 112.51, 111.31, 110.04, 55.89, 22.91; HR-ESI: [M + H]+ calcd. for
C18H15BrN3O2 384.0342, found: 384.0338.
14h: White solid, Yield 80%; 1H NMR (400 MHz, CD3OD):
7.08 (t, 1H), 6.98 (t, 1H), 4.15 (s, 2H), 2.84 (t, 2H), 1.72 (m, 2H), 1.35 (m, 2H), 0.91 (t, 3H); 13C NMR
(125 MHz, CD3OD): 181.73, 171.02, 138.12, 128.32, 124.46, 122.54, 119.85, 119.30, 112.29, 109.79, 29.59,
26.83, 23.18, 23.06, 13.80; HR-ESI: [M + H]+ calcd. for C15H18N3O 256.1372, found: 256.1377.
δ 7.51 (d, 1H), 7.33 (d, 1H), 7.16 (s, 1H),
δ
14i: White solid, Yield 65%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 6.98 (t, 1H), 4.17 (s, 2H), 4.06 (t, 2H), 2.91 (t, 2H), 2.00 (s, 3H), 1.85 (m, 2H), 1.69 (m, 2H); 13
δ 7.51 (d, 1H), 7.33 (d, 1H), 7.17 (s, 1H), 7.09
C
NMR (125 MHz, CD3OD):
δ 181.33, 172.92, 171.12, 138.14, 128.34, 124.48, 122.55, 119.86, 119.32, 112.30,
109.79, 64.90, 28.92, 26.70, 24.09, 23.20, 20.74; HR-ESI: [M + H]+ calcd. for C17H20N3O3 314.1499, found:
314.1500.
1
14j: White solid, Yield 70%; H NMR (400 MHz, CD3OD):
δ 7.53 (d, 1H), 7.33 (d, 1H), 7.16 (s, 1H),
7.08 (t, 1H), 6.99 (t, 1H), 4.15 (s, 2H), 3.17 (m, 1H), 1.32 (d, 6H), 1.35 (m, 2H), 0.91 (t, 3H); 13C NMR
(125 MHz, CD3OD): 185.49, 170.96, 138.10, 128.33, 124.47, 122.54, 119.86, 119.31, 112.29, 109.77, 28.54,
23.22, 20.32; HR-ESI: [M + H]+ calcd. for C14H16N3O 242.1215, found: 242.1212.
δ
14k: White solid, Yield 65%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 7.00 (t, 1H), 4.24 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ
7.55 (d, 1H), 7.35 (m, 2H), 7.19 (s, 1H), 7.10
175.37, 172.18, 138.08, 128.24, 124.62,
δ
122.62, 119.96, 119.26, 112.34, 109.19, 59.86, 23.21; HR-ESI: [M + H]+ calcd. for C12H10Cl2N3O 282.0123,
found: 282.0127.
14p: White solid, Yield 65%; 1H NMR (400 MHz, CD3OD):
7.17 (s, 1H), 7.13 (s, 1H), 7.09 (m, 2H), 6.97 (t, tH), 4.32 (s, 2H), 4.14 (s, 2H); 13C NMR (125 MHz,
δ 7.50 (d, 1H), 7.45 (d, 1H), 7.33 (dd, 2H),
CD3OD): δ 178.67, 169.88, 136.35, 136.24, 123.12, 122.56, 122.35, 120.02, 119.76, 119.76, 119.06, 118.76,
111.42, 111.32, 109.82, 107.95, 23.47, 22.78; HR-ESI: [M + H]+ calcd. for C20H17N4O 329.1397, found:
329.1388.
14q: White solid, Yield 74%; 1H NMR (400 MHz, CD3OD):
(d, 1H), 7.12 (s, 1H), 7.07 (t, 1H), 6.97 (t, 1H), 6.87 (t, 1H) 4.25 (s, 2H), 4.13 (s, 2H); 13C NMR (125 MHz
CD3OD): 180.53, 171.21, 159.80, 158.26, 138.07, 134.57, 128.43, 128.36, 128.29, 126.73, 124.46, 122.54,
δ 7.50 (d, 1H), 7.29 (m, 2H), 7.20 (s, 1H), 7.16
,
δ
119.89, 119.31, 113.29, 113.22, 112.27, 110.98, 110.80, 109.74, 108.29, 108.25, 103.96, 103.80, 23.74, 23.17;
HR-ESIMS: [M − H]− calcd. for C20H14FN4O 345.1157, found: 345.1161.
14r: White solid, Yield 78%; 1H NMR (400 MHz, CD3OD):
7.14 (s, 1H), 7.08 (m, 2H), 6.97 (t, 1H), 4.31 (s, 2H), 4.16 (s, 2H); 13C NMR (125 MHz, CD3OD):
171.27, 138.11, 136.45, 129.22, 128.33, 126.51, 125.99, 124.46, 122.94, 122.54, 119.90, 119.31, 118.69, 113.67,
δ
7.51 (m, 2H), 7.31 (m, 2H), 7.24 (s, 1H),
180.47,
δ
112.28, 109.77, 108.00, 23.69, 23.19; HR-ESIMS: [M
361.0858.
−
H]− calcd. for C20H14ClN4O 361.0862, found:

Mar. Drugs 2018, 16, 97
12 of 14
14s: White solid, Yield 82%; 1H NMR (400 MHz, CD3OD):
δ
7.66 (d, 1H), 7.51 (d, 1H), 7.32 (d, 1H), 7.20
(m, 2H), 7.14 (s, 1H), 7.08 (t, 1H), 6.98 (t, 1H), 4.30 (s, 2H), 4.15 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ
180.44, 171.26, 138.11, 136.69, 129.88, 128.33, 126.35, 125.54, 124.46, 122.54, 121.84, 119.91, 119.31, 114.10,
113.38, 112.28, 109.76, 107.90, 23.67, 23.18; HR-ESIMS: [M
found: 405.0356.
−
H]− calcd. for C20H14BrN4O 405.0356,
14t: White solid, Yield 88%; 1H NMR (400 MHz, CD3OD):
δ 7.51 (m, 2H), 7.31 (m, 2H), 7.24 (s, 1H),
7.14 (s, 1H), 7.08 (m, 2H), 6.97 (t, 1H), 4.31 (s, 2H), 4.16 (s, 2H); 13C NMR (125 MHz, CD3OD):
171.27, 138.11, 136.45, 129.22, 128.33, 126.51, 125.99, 124.46, 122.94, 122.54, 119.90, 119.31, 118.69, 113.67,
δ 180.47,
112.28, 109.77, 108.00, 23.69, 23.19; HR-ESIMS: [M
361.0870.
−
H]− calcd. for C20H14ClN4O 361.0862, found:
14u: White solid, Yield 82%; 1H NMR (400 MHz, CD3OD):
(s, 1H), 7.08 (t, 1H), 7.03 (t, 1H), 6.96 (m, 2H), 4.54 (s, 2H), 4.13 (s, 2H); 13C NMR (125 MHz, CD3OD):
δ 7.49 (d, 1H), 7.29 (t, 2H), 7.21 (s, 1H), 7.10
δ
181.46, 171.12, 139.70, 138.08, 123.37, 122.51, 120.86, 119.85, 119.33, 112.24, 111.62, 109.78, 107.89, 25.42,
23.21; HR-ESIMS: [M − H]− calcd. for C20H14ClN4O 361.0862, found: 361.0864.
3.1.8. Synthesis of Compound 14l−14o
To a solution of acyl chloride (2.7 mmol, 1.0 equiv) and potassium carbonate (3.2 mmol, 1.2 equiv)
in toluene (10 mL), compound 12 (2.7 mmol, 1.0 equiv) was added and under reflux for 4 h. The
mixture was filtered, and the residue was washed with CH2Cl2; then, the solution was combined and
concentrated. The residue was subjected to silica gel chromatography with petroleum ether/EtOAc
(5:1) to give compounds 14l−14o.
14l: White solid, Yield 60%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 6.98 (t, 1H), 4.16 (s, 2H), 3.75 (m, 1H), 2.39 (m, 4H), 2.08 (m, 2H); 13C NMR (125 MHz, CD3OD):
183.61, 171.03, 138.09, 128.33, 124.48, 122.54, 119.86, 119.30, 112.29, 109.77, 32.52, 27.98, 23.22, 19.57;
HR-ESIMS: [M + H]+ calcd. for C15H16N3O 254.1288, found: 254.1285.
δ 7.53 (d, 1H), 7.33 (d, 1H), 7.17 (s, 1H), 7.09
δ
14m: White solid, Yield 65%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 6.98 (t, 1H), 4.16 (s, 2H), 3.75 (m, 1H), 2.39 (m, 4H), 2.08 (m, 2H); 13C NMR (125 MHz, CD3OD):
183.61, 171.03, 138.09, 128.33, 124.48, 122.54, 119.86, 119.30, 112.29, 109.77, 32.52, 27.98, 23.22, 19.57;
HR-ESIMS: [M + H]+ calcd. for C16H18N3O 268.1382, found: 268.1391.
δ 7.53 (d, 1H), 7.33 (d, 1H), 7.17 (s, 1H), 7.09
δ
14n: White solid, Yield 60%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 6.99 (t, 1H), 4.16 (s, 2H), 2.95 (m, 1H), 2.03 (m, 2H), 1.80 (m, 2H); 1.59 (m, 2H); 1.42 (m, 2H); 1.32
δ 7.53 (d, 1H), 7.33 (d, 1H), 7.16 (s, 1H), 7.09
(m, 2H); 13C NMR (125 MHz, CD3OD):
δ 184.49, 170.88, 138.12, 128.34, 124.46, 122.54, 119.85, 119.31,
112.29, 109.77, 37.42, 31.25, 30.76, 26.62, 23.34; HR-ESIMS: [M + H]+ calcd. for C17H20N3O 282.1601,
found: 282.1603.
14o: White solid, Yield 63%; 1H NMR (400 MHz, CD3OD):
(t, 1H), 7.60 (m, 2H), 7.34 (d, J = 8.13 Hz 1H), 7.24 (s, 1H), 7.09 (t, 1H), 7.02 (t, 1H), 4.31 (s, 2H); 13C NMR
δ 8.72 (d, 1H), 8.24 (d, J = 7.92 Hz, 1H), 8.03
(125 MHz, CD3OD):
δ 175.36, 172.34, 151.26, 144.35, 139.54, 138.14, 128.45, 125.58, 124.62, 122.59, 119.93,
119.33, 112.33, 109.70, 23.38; HR-ESIMS: [M + H]+ calcd. for C16H13N4O 277.1084, found: 277.1089.
3.2. Biological Assay
For screening of PTP1B and TCPTP, 2
were transferred into individual wells of 96-well flat bottom plates, to give a final concentration of
20 M of extract in 2% DMSO. After incubation with the enzymes for 15 min, 10 times-concentrated
substrates were added to initiate the enzymatic reaction, and the resultant enzymatic activity
µL of the stock solution of each compoud (1 mM) in DMSO
µ

Mar. Drugs 2018, 16, 97
13 of 14
normalized against the control (2% DMSO) to obtain the inhibition rate of the compound. When the
inhibition rate was more than 50% at 20 M, the dose–response inhibition assay of the compound was
µ
performed to determine the 50% percentage inhibition concentrations (IC50).
3.3. Molecular Docking
The LigPrep panel was employed to generate stereoisomers and protonation states of our
compounds with Epik integrated in Maestro 9.1 (Schrödinger, LLC, New York, NY, USA, 2010) [20,21].
The crystal structure of hPTB1B (PDB access code: 2QBP) was retrieved from the Protein Data Bank
(http://www.rcsb.org/pdb/home/home.do) and chosen as the receptor for molecular docking. The
Protein Preparation Wizard module integrated in the Maestro program suite was applied to prepare
the receptor [22]. Docking simulations were performed using the GLIDE 5.5 (Grid-based Ligand
Docking with Energetics) program with the extra precision (XP) mode. Other parameters were set as
the default.
Acknowledgments: This research work was financially supported by the Natural Science Foundation of China
(Nos. 41676073, 81520108028, 81603022), NSFC-Shandong Joint Fund for Marine Science Research Centers (No.
U1606403), the SKLDR/SIMM Projects (SIMM 1705ZZ-01). Xu-Wen Li is thankful for the financial support of
Shanghai “Pujiang Program” (No. 16PJ1410600), “Youth Innovation Promotion Association” (No. 2016258) from
Chinese Academy of Sciences, “Young Elite Scientists Sponsorship” from China Association for Science and
Technology (No. 2016QNRC001), and the SA-SIBS Scholarship Program.
Author Contributions: Jin Liu, Xu-Wen Li and Yue-Wei Guo conceived and designed the experiments. Jin Liu,
Xu-Wen Li, Jing-Ya Li and Yu Chen performed the experiments. Yue-Wei Guo, Xu-Wen Li, Yu Chen, Cheng Luo,
Jia Li and Kai-Xian Chen analyzed the data. Xu-Wen Li and Yue-Wei Guo wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
Tobin, J.F.; Tam, S. Recent advances in the development of small molecule inhibitors of PTP1B for the
treatment of insulin resistance and type 2 diabetes. Curr. Opin. Drug Discov. Dev. 2002, 5, 500–512.
Liu, G.; Trevillyan, J.M. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose
tolerance and type II diabetes. Curr. Opin. Investig. Drugs 2002, 3, 1608–1616. [PubMed]
Johnson, T.O.; Ermolieff, J.; Jirousek, M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev.
Drug Discov. 2002, 1, 696–709. [CrossRef] [PubMed]
Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.;
Himms-Hagen, J.; Chan, C.C.; et al. Increased insulin sensitivity and obesity resistance in mice lacking the
protein tyrosine phosphatase-1B gene. Science 1999, 283, 1544–1548. [CrossRef] [PubMed]
Klaman, L.D.; Boss, O.; Peroni, O.D.; Kim, J.K.; Martino, J.L.; Zabolotny, J.M.; Moghal, N.; Lubkin, M.;
Kim, Y.B.; Sharpe, A.H.; et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin
sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20, 5479–5489. [CrossRef]
[PubMed]
5.
6.
7.
Taylor, S.D.; Hill, B. Recent advances in protein tyrosine phosphatase 1B inhibitors. Expert Opin. Investig.
Drugs 2004, 13, 199–214. [CrossRef] [PubMed]
Iversen, L.F.; Moler, K.B.; Pedersen, A.K.; Peters, G.H.; Petersen, A.S.; Andersen, H.S.; Branner, S.;
Mortensen, S.B.; Moller, N.P.H. Structure determination of T cell protein-tyrosine phosphatase. J. Biol.
Chem. 2002, 277, 19982–19990. [CrossRef] [PubMed]
8.
9.
Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. Nat. Prod.
Rep. 2012, 29, 144–222. [CrossRef] [PubMed]
Ye, F.; Zhu, Z.D.; Chen, J.S.; Li, J.; Gu, Y.C.; Zhu, W.L.; Li, X.W.; Guo, Y.W. Xishacorenes A–C, Diterpenes with
Bicyclo[3.3.1]nonane Nucleus from the Xisha Soft Coral Sinularia polydactyla. Org. Lett. 2017, 19, 4183–4186.
[CrossRef] [PubMed]
10. Li, X.L.; Kurtán, T.; Hu, J.C.; Mándi, A.; Li, J.; Li, X.W.; Guo, Y.W. Structural and Stereochemical Studies
of Laurokamurols A–C, Uncommon Bis-sesquiterpenoids from the Chinese Red Alga Laurencia okamurai
Yamada. J. Agric. Food Chem. 2017, 65, 1550–1555. [CrossRef] [PubMed]

Mar. Drugs 2018, 16, 97
14 of 14
11. Zhou, Z.F.; Wang, X.; Zhang, H.; Sun, J.Y.; Zheng, L.H.; Liu, H.C.; Wang, J.D.; Shen, A.J.; Geng, M.Y.;
Guo, Y.W. Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium
Chromobacterium sp. HS-13-94. Acta Pharm. Sin. B 2015, 5, 62–66. [CrossRef] [PubMed]
12. Carbone, M.; Li, Y.; Irace, C.; Mollo, E.; Castelluccio, F.; Pascale, A.D.; Cimino, G.; Santamaria, R.; Guo, Y.W.;
Gavagnin, M. Structure and cytotoxicity of phidianidines A and B: First finding of 1,2,4-oxadiazole system
in a marine natural product. Org. Lett. 2011, 13, 2516–2519. [CrossRef] [PubMed]
13. Lin, H.Y.; Snider, B.B. Synthesis of phidianidines A and B. J. Org. Chem. 2012, 77, 4832–4836. [CrossRef]
[PubMed]
14. Brogan, J.T.; Stoops, S.L.; Lindsley, C.W.T. Total synthesis and biological evaluation of phidianidines A and B
uncovers unique pharmacological profiles at CNS targets. ACS Chem. Neurosci. 2012, 3, 658–664. [CrossRef]
[PubMed]
15. Jiang, C.S.; Fu, Y.; Zhang, L.; Gong, J.X.; Wang, Z.Z.; Xiao, W.; Zhang, H.Y.; Guo, Y.W. Synthesis and
biological evaluation of novel marine-derived indole-based 1,2,4-oxadiazoles derivatives as multifunctional
neuroprotective agents. Bioorg. Med. Chem. Lett. 2015, 25, 216–220. [CrossRef] [PubMed]
16. Zhang, L.; Jiang, C.S.; Gao, L.X.; Gong, J.X.; Wang, Z.Z.; Li, J.Y.; Li, J.; Li, X.W.; Guo, Y.W. Design, synthesis
and in vitro activity of phidianidine B derivatives as novel PTP1B inhibitors with specific selectivity. Bioorg.
Med. Chem. Lett. 2016, 26, 778–781. [CrossRef] [PubMed]
17. Yang, S.H.; Chang, S. Highly efficient and catalytic conversion of aldoximes to nitriles. Org. Lett. 2001, 3,
4209–4211. [CrossRef] [PubMed]
18. Hamzé, A.; Hernandez, J.F.; Fulcrand, P.; Martinez, J. Synthesis of Various 3-Substituted
1,2,4-Oxadiazole-Containing Chiral
Chem. 2003, 68, 7316–7321. [CrossRef] [PubMed]
β α-Amino Acids from Fmoc-Protected Aspartic Acid. J. Org.
3- and
19. Buchanan, J.C.; Petersen, B.P.; Chamberland, S. Concise total synthesis of phidianidine A and B. Tetrahedron
Lett. 2013, 54, 6002–6004. [CrossRef]
20. Furdas, S.D.; Shekfeh, S.; Bissinger, E.M.; Wagner, J.M.; Schlimme, S.; Valkov, V.; Hendzel, M.; Jung, M.;
Sippl, W. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors.
Bioorg. Med. Chem. 2011, 19, 3678–3689. [CrossRef] [PubMed]
21. Shelley, J.C.; Cholleti, A.; Frye, L.L.; Greenwood, J.R.; Timlin, M.R.; Uchimaya, M. Epik: A software program
for pK a prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des.
2007, 21, 681–691. [CrossRef] [PubMed]
22. Chimenti, F.; Bizzarri, B.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Fioravanti, R.; Granese, A.;
Carradori, S.; Tosi, F.; et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network:
Cyclopentylidene-[4-(40-chloropenty)thiazol-2-yl] hydrazine. J. Med. Chem. 2009, 52, 530–536. [CrossRef]
[PubMed]
©
2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).